臨床研究支援事業

CSP-A-TOP《骨粗鬆症至適療法研究支援事業》

Comprehensive Support Project for Adequate Treatment of Osteoporosis

成果一覧

J-06

JOINT-06

J Bone Miner Metab. 2025 DOI : 10.1007/s00774-025-01586-y

Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: Interim report (end of 52-week treatment) of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06) Soen S, Uemura Y, Tanaka S, Takeuchi Y, Endo N, Takada J, Ikeda S, Iwamoto J, Okimoto N, Tanaka Sa.

J Bone Miner Metab. 2024;42(5):582-590.　DOI：10.1007/s00774-024-01521-7

A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06) Soen S, Uemura Y, Tanaka S, Takeuchi Y, Endo N, Takada J, Ikeda S, Iwamoto J, Okimoto N. Tanaka Sa.

J-05

JOINT-05

J Bone Miner Metab. 2025 May 27. doi: 10.1007/s00774-025-01610-1.

Evaluation of the fracture prevention effects of teriparatide and alendronate in patients with frailty: a sub-analysis of the Japanese osteoporosis intervention trial-05 Tatsuya Hosoi, Makoto Yunoki, Shiro Tanaka, Hiroshi Hagino, Satoshi Mori, Satoshi Soen, Sumito Ogawa

Osteoporos Int. 2024;35(12):2175-2182. doi: 10.1007/s00198-024-07260-9.

Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05 Takeuchi Y, Tanaka S, Kuroda T, Hagino H, Mori S, Soen S.

J Bone Miner Metab. 2024;42(6):675-680. doi: 10.1007/s00774-024-01541-3.

Predictors of discontinuation of osteoporosis treatment: sub‑analysis of the Japanese osteoporosis intervention trial‑05 (JOINT‑05). Takeuchi Y, Nakatsuka Y, Tanaka S, Kuroda T, Hagino H, Mori S, Soen S.

J Bone Miner Metab. 2024;42(3):382-388. doi: 10.1007/s00774-024-01515-5.

Achieving osteoporosis treat‑to‑target goals with teriparatide or alendronate: sub‑analysis of Japanese Osteoporosis Intervention Trial‑05 (JOINT‑05). Hagino H, Tanaka S, Kuroda T, Mori S, Soen S.

J Bone Miner Metab. 2023;41(6):854-864. doi: 10.1007/s00774-023-01466-3.

Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05) Taguchi A, Tanaka S, Ozaki T, Arai K, Mori S, Ohta H, Hagino H, Tanaka Sa, Shiraki M, Nakamura T, Soen S

JBMR Plus. 2022;6(10):e10673. doi: 10.1002/jbm4.10673.

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial-05 (JOINT-05) Tanaka S, Saito M, Hagino H, Mori S, Nakamura T, Ohta H, Sone T, Takahashi K, Mitomo Y, Sugimoto T, Soen S

Osteoporos Int. 2023;34(1):189-199. doi: 10.1007/s00198-022-06570-0.

Sequential therapy with once‑weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial‑05. Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S.

Osteoporos Int. 2021;32(11):2301-2311. doi: 10.1007/s00198-021-05996-2.

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S.

J Bone Miner Metab. 2020;38(3):412-417. doi: 10.1007/s00774-019-01074-0.

Design of a randomized trial of teriparatide followed by alendronate:Japanese Osteoporosis Intervention Trial‑05 (JOINT‑05). Tanaka S, Mori S, Hagino H, Sugimoto T.

J-04

JOINT-04

Calcif Tissue Int. 2015;97(6):542-550. doi: 10.1007/s00223-015-0045-y.

Impact of osteonecrosis of the jaw on osteoporosis treatment in Japan: Results of a questionnaire-based survey by the adequate treatment of osteoporosis (A-TOP) Research Group. Taguchi A, Shiraki M, Tsukiyama M, Miyazaki T, Soen S, Ohta H, Nakamura T, Orimo H.

Arch Osteoporos. 2021;17(1):7. doi: 10.1007/s11657-021-01054-w.

Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05. Taguchi A, Uemura Y, Tanaka S, Ohta H, Mori S, Hagino H, Shiraki M, Nakamura T, Soen S. group.

J Bone Miner Metab. 2021;39:668-677. doi: 10.1007/s00774-021-01208-3.

Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study. Hagino H, Uemura Y, Mori S, Sone T, Ohta H, Nakamura T.

Curr Med Res Opin. 2020;36(11),1847-1859. doi: 10.1080/03007995.2020.1816537.

Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.　 Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M

J Bone Miner Metab. 2019;37(5):886-892. doi: 10.1007/s00774-019-00990-5.

Incidence of osteonecrosis of the jaw in Japanese osteoporosis　patients taking minodronic acid. Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M.

J Bone Miner Metab. 2019;37(3),491-495. doi: 10.1007/s00774-018-0942-z.

Study design of multi-center, open-label randomized controlled, head-to-headtrial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M.

J-03

JOINT-03

Osteoporos Int. 2017;28(6),1893-1901.DOI 10,1007/S 00198-017-3966-7

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M.

J Bone Miner Metab. 2017;35(4);385-395. DOI 10.1007/s00774-016-0768-5

Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Tanaka S, Miyazaki, T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J Bone Miner Metab. 2014;32(3):298-304. doi: 10.1007/s00774-013-0491-4.

Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J-02

JOINT-02

J Orthop Sci. 2021;26(6):1085-1093. doi: 10.1016/j.jos.2020.10.017.

Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy. Itoi E, Uemura Y, Ohta H, Nakamura T, Fukunaga M, Orimo H, Shiraki M.

Clin Ther. 2014;36(2):225-235. doi: 10.1016/j.clinthera.2013.12.007.

Serum 25 hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with high risk for fracture. Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Y, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J Bone Miner Metab. 2015;33(6):642-650. doi: 10.1007/s00774-014-0625-3.

Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan. Uemura Y, Miyakawa N, Orimo H, Shiraki M, Nakamura T, Mori S.

Curr Med Res Opin. 2011;27(6):1273-1284. doi:10.1185/03007995.2011.580341.

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)- 02. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M

J Bone Miner Metab. 2011;29(1):37-43. doi: 10.1007/s00774-010-0188-x.

Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial(JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A, Tanaka S, Tanaka Y, Hosoi T, Itoi E, Morimoto S, Itabashi A, Sugimoto T, Yamashita T, Gorai I, Mori S, Kishimoto H, Mizunuma H, Endo N, Nishizawa Y, Takaoka K, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H.

A-01

JOB

J Epidemiol. 2023 5;33(12):633-639. doi: 10.2188/jea.JE20220099.

Antiresorptive drugs and the risk of femoral shaft fracture in men and women with osteoporosis: A cohort study using the national database of health insurance claims of Japan Imai T, Hosoi T, Hagino H, Yamamoto T, Kuroda T, Watanabe H, Tanaka S.

Jpn J Pharmacoepidemiol. 2016;21(1);13-19 doi.org/10.3820/jjpe.21.13

Validation study of claims-based definitions of suspected atypical femoral fractures using clinical information. Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T.